Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study

Yoshino, T.Kim, T. W.Yong, W. P.Shiu, K-K.Jensen, B. VittrupJensen, L. HenrikSmith, D.Garcia-Carbonero, R.Alcaide-Garcia, J.Gibbs, P.de la Fouchardiere, C.Rivera, F.Elez, E.Bendell, J.Le, D. T.Yang, P.Farooqui, M.Marinello, P.Diaz, L. A.Andre, T.2025-01-072025-01-072020-11-010923-7534https://hdl.handle.net/10668/24353enPembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 studyconference outputopen access10.1016/j.annonc.2020.10.1321569-8041http://www.annalsofoncology.org/article/S0923753420426237/pdf600988900113